VANCOUVER, British Columbia, May 17, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (“MDMA”)…

Source

Previous articlePT410 – Manufacturing MDMA and Why Creating MDMA Analogs Is So Important
Next articleFILAMENT HEALTH ANNOUNCES FIRST EVER NAGOYA PROTOCOL-COMPLIANT SHIPMENT OF IBOGA FROM GABON